Advertisement
Perspectives

Inhaled corticosteroids in COPD: when are they needed, when not needed and when harmful?

PETER A. FRITH, IAN A. YANG, Kerry Hancock
Full Text: PDF
OPEN ACCESS

Quick links

 

Advertisement
Advertisement

References

1.    GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1260-1344.
2.    Yang IA, Brown JL, George J, et al. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Med J Aust 2017; 207: 436-442.
3.    Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD; 2018. Available online at: http://goldcopd.org (accessed September 2018).
4.    Agusti A, Celli B, Faner R. What does endotyping mean for treatment in chronic obstructive pulmonary disease? Lancet 2017; 390: 980-987.
5.    Thoracic Society of Australia and New Zealand. Guidelines for the management of chronic obstructive pulmonary disease. TSANZ Statement. Mod Med Aust 1995; 38(7): 132-146.
6.    McKenzie DK, Frith PA, Burdon JG, Town GI; Australian Lung Foundation; Thoracic Society of Australia and New Zealand. The COPDX plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2003. Med J Aust 2003; 178 Suppl: S7-S39.
7.    National Asthma Council Australia. Australian asthma handbook, version 1.3. Melbourne: National Asthma Council Australia; 2017. Available online at: www.asthmahandbook.org.au (accessed September 2018).
8.    Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. GINA; 2018. Available online at: www.ginasthma.org (accessed September 2018).
9.    Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; (7): CD002991.
10.    Brode SK, Campitelli MA, Kwong JC, et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J 2017; 50: pii: 1700037. 
11.    Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001-1006.
12.    Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-166.
13.    Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011; 66: 699-708.
14.    Finney L, Berry M, Singanayagam A, et al. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Resp Med 2014; 2: 919-932.
15.    Shaaban H, Daniel S, Sison R, Slim J, Perez G. Eosinopenia: is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital? J Crit Care 2010; 25: 570-575.
16.    Holland M, Alkhalil M, Chandromouli S, Janjua A, Babores M. Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease. Respirology 2010; 15: 165-167.
17.    Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Resp Med 2016; 4: 390-398.
18.    Beghe B, Verduri A, Roca M, Fabbri LM. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J 2013; 41: 993-995.
19.    Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
20.    Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
21.    Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21: 68-73.
22.    Martinez FJ, Vestbo J, Anderson JA, et al. Effect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstruction. Am J Respir Crit Care Med 2017; 195: 881-888.
23.    Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med 2016; 375: 1253-1260.
24.    Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev 2014; (3): CD010844.
25.    Stolz D, Hirsch HH, Schilter D, et al. Intensified therapy with inhaled corticosteroids and long-acting beta2-agonists at the onset of upper respiratory tract infection to prevent chronic obstructive pulmonary disease exacerbations. a multicenter, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2018; 197: 1136-1146.
26.    Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Resp Med 2018; 6: 117-126.
27.    Yang IA, Dabscheck E, George J, et al. The COPD-X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2018. Brisbane: Lung Foundation Australia; 2018. Available online at: www.copdx.org.au (accessed September 2018).
28.    Primary Care Respiratory Society UK (PCRS). Evaluation of appropriateness of inhaled corticosteroid (ICS) therapy in COPD and guidance on ICS withdrawal. Solihull, UK: PCRS; 2018. Available online at: www.pcrs-uk.org/sites/pcrs-uk.org/files/SteppingDownICS_FINAL4.pdf (accessed September 2018).
29.    Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis 2015; 10: 2207-2217.
30.    Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371: 1285-1294.
31.    Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018; 198: 329-339. 
32.    Vogelmeier CF, Gaga M, Aalamian-Mattheis M, et al; CRYSTAL study investigators. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res 2017; 18: 140.
33.    Frith PA, Ashmawi S, Krishnamurthy S, et al; FLASH Investigators. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology 2018 Aug 3. doi: 10.1111/resp.13374. [Epub ahead of print].

Pages

Quick links

Professor Frith is Professor in Respiratory Medicine at the College of Medicine and Public Health, Flinders University, Adelaide; and Adjunct Professor in Health Sciences at the Alliance for Research in Exercise, Nutrition and Activity (ARENA), University of South Australia, Adelaide, SA. Professor Yang is Head of the Northside Clinical School, The University of Queensland; and Thoracic Program Medical Director at The Prince Charles Hospital, Brisbane, Qld. Dr Hancock is a GP Principal at Chandlers Hill Surgery, Adelaide, SA; an Executive Member of the COPD Coordinating Committee of Lung Foundation Australia (LFA); Chair of the GP Advisory Committee, LFA; and Chair of the Respiratory Medicine Network, Specific Interests Faculty, RACGP.

Tools